Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH

Tumori. 2015 Apr 28;101(2):e51-3. doi: 10.5301/tj.5000249.

Abstract

Hyponatremia frequently occurs in patients with cancer and is mostly due to a syndrome of inappropriate antidiuresis caused by ectopic secretion of antidiuretic hormone (SIADH). Small cell lung cancer presents with SIADH in approximately 11%-15% of cases. Recently, a new class of drugs, vasopressin V2-receptor antagonists (vaptans), emerged as a promising treatment for SIADH, but efficacy and safety data in cancer patients are lacking. We present a case of SIADH, heralding small cell lung cancer and persisting after apparent complete remission of primary tumor following chemotherapy/radiotherapy, in a patient who underwent long-term treatment with tolvaptan without any serious adverse effects.

Publication types

  • Case Reports

MeSH terms

  • Antidiuretic Hormone Receptor Antagonists / administration & dosage
  • Antidiuretic Hormone Receptor Antagonists / adverse effects
  • Antidiuretic Hormone Receptor Antagonists / therapeutic use*
  • Benzazepines / administration & dosage
  • Benzazepines / adverse effects
  • Benzazepines / therapeutic use*
  • Chemoradiotherapy
  • Drug Administration Schedule
  • Female
  • Humans
  • Hyponatremia / drug therapy
  • Hyponatremia / etiology*
  • Hyponatremia / prevention & control*
  • Inappropriate ADH Syndrome / complications*
  • Inappropriate ADH Syndrome / drug therapy*
  • Inappropriate ADH Syndrome / etiology
  • Lung Neoplasms / complications*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / therapy
  • Middle Aged
  • Remission Induction
  • Small Cell Lung Carcinoma / complications*
  • Small Cell Lung Carcinoma / metabolism
  • Small Cell Lung Carcinoma / therapy
  • Tolvaptan
  • Treatment Outcome

Substances

  • Antidiuretic Hormone Receptor Antagonists
  • Benzazepines
  • Tolvaptan